Heiko Müller, Frank Dicker, Constance Bär, Wencke Walter, Stephan Hutter, Niroshan Nadarajah, Manja Meggendorfer, Qingsong Gao, Ilaria Iacobucci, Charles G. Mullighan, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach
{"title":"Proximally biased V(D)J recombination in the clonal evolution of IGH alleles in KMT2A::AFF1 BCP-ALL of all age classes","authors":"Heiko Müller, Frank Dicker, Constance Bär, Wencke Walter, Stephan Hutter, Niroshan Nadarajah, Manja Meggendorfer, Qingsong Gao, Ilaria Iacobucci, Charles G. Mullighan, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach","doi":"10.1002/hem3.71","DOIUrl":null,"url":null,"abstract":"<p>We report the analysis of 379 cases of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) using whole-transcriptome sequencing data (Table S1 and Supporting Information S1: Methods). In 48 adult, 36 pediatric, and 37 infant cases of BCP-ALL carrying t(4;11)(q21;q23)/<i>KMT2A::AFF1</i> rearrangements (KMT2A-r), we observed strongly favored usage of proximal IGHV genes in V(D)J recombination and more abundant de novo DJ<sub>H</sub> recombination than in other BCP-ALL subtypes. This finding has implications for the detection of measurable residual disease (MRD) in clinical practice as MRD-guided treatment choices have proved to provide valuable guidance in a disease that is still associated with poor prognosis in all age categories.</p><p>BCP-ALL carrying KMT2A-r is an aggressive leukemia with poor prognosis characterized by the sudden occurrence of very high white blood cell counts, a slight preference for female patients, rapid progression, and significantly shorter survival than KMT2A-r-negative patients.<span><sup>1, 2</sup></span> Treatment options that significantly prolong the survival of affected patients are limited to allogeneic stem cell transplantation.<span><sup>2</sup></span> The incidence of KMT2A-r BCP-ALL is estimated between 4% and 10% in adults and 3% and 4% in childhood.<span><sup>3</sup></span></p><p>KMT2A is a histone methyl transferase of the trithorax group involved in the establishment of epigenetic memory. It catalyzes H3K4 methylation of a large number of physiological targets including HOX genes, supporting activation of their expression.<span><sup>4, 5</sup></span> In leukemogenic fusions, the N-terminal portion of <i>KMT2A</i> is fused in frame to more than 100 fusion partners.<span><sup>6</sup></span> In the fusion product, the catalytic SET domain of KMT2A is lost. The most frequently observed fusion partners favor the interaction of the fusion product with another histone methyl transferase (DOT1L) that catalyzes H3K79 methylation. As a consequence, proper regulation of target genes activated in this aberrant fashion appears to be disturbed in cells carrying KMT2A-r.<span><sup>4, 5, 7, 8</sup></span></p><p>Proximally biased V(D)J recombination was first described in pre-B-cell lines<span><sup>9</sup></span> and later shown to depend on <i>Pax5</i> function.<span><sup>10</sup></span> It is now understood that the generation of a randomized immunoglobulin repertoire depends on chromatin modifications at the IGH locus controlled by <i>PAX5</i> and its target, <i>WAPL</i>.<span><sup>11, 12</sup></span> In addition to classical V(D)J recombination,<span><sup>13</sup></span> B-cell receptors (BCRs) are known to be modified by direct V<sub>H</sub> to V<sub>H</sub>DJ<sub>H</sub> recombination (V<sub>H</sub> replacement)<span><sup>14, 15</sup></span> and this process is known to occur also in BCP-ALL cells.<span><sup>16-18</sup></span> Whether the relative contribution of V(D)J recombination and V<sub>H</sub> replacement to clonal evolution of BCRs displays BCP-ALL subtype specificity is currently a matter of investigation.<span><sup>19, 20</sup></span></p><p>During the analysis of BCR rearrangements in RNA-sequencing (RNA-Seq) data from BCP-ALL samples, we noticed an unusual abundance of rearrangements involving <i>IGHV6-1</i> in samples carrying KMT2A-r fusion genes. To quantify this observation, we employed MiXCR analysis of RNA-Seq reads (Figure 1). The number of RNA-Seq reads mapping to a particular IGHV gene by MiXCR was used to quantify the expression levels of individual IGHV genes in a sample. The heatmap in Figure 1 shows the results of this analysis. In this heatmap, the IGHV genes are ordered according to their proximity in terms of genomic distance to the cluster of DJ<sub>H </sub>segments in the IGH locus. While for most samples, the expression level of IGHV genes appears to be independent of their genomic position, in KMT2A-r samples the most proximal IGHV gene IGHV6-1 displays significantly higher expression levels as compared to distal ones. This observation is true for KMT2A-r samples of all age classes.</p><p>We employed junction analysis of MiXCR-derived nucleotide sequences of rearranged IGH alleles to test whether there are BCP-ALL-subtype-specific differences in V(D)J recombination. IMGT-V-QUEST was used for this purpose, which identifies as junctions the nucleotides coding for the amino acids encompassing the anchor positions of the CDR3 region (C104-W118) and maps the nucleotides to the V<sub>H</sub>-N-D-N-J<sub>H</sub> components of the CDR3 region (Table S2). The results are shown in Figure 2. We observed that KMT2A-r samples of all age classes have a median number of three DNJ<sub>H</sub> stems per sample (Figure 2A). The only subtype with a similar median number of DNJ<sub>H</sub> stems per sample is <i>t(1;19)/TCF3::PBX1</i>. At the other end of the spectrum is the <i>DUX4</i> subtype where multiple DNJ<sub>H</sub> stems per sample were not detected. Furthermore, the CDR3 regions at the nucleotide level identified in KMT2A-r samples are shorter than in most other BCP-ALL subtypes (Figure 2B).</p><p>We conclude that V(D)J recombination is proximally biased in samples with KMT2A-r of all age classes. Proximally biased V(D)J recombination leads to preferential usage of <i>IGHV6-1</i> in BCR rearrangements. Indeed, up to 50% of samples with KMT2A-r harbor BCRs involving <i>IGHV6-1</i>.</p><p>We detected subtype specificity in the clonal evolution of BCP-ALL. We observed more DNJ<sub>H</sub> stems in KMT2A-r samples as compared to other types of BCP-ALL, and the CDR3 regions in KMT2A-r samples are shorter. This is in line with the observations reported by Darzentas et al.,<span><sup>19, 20</sup></span> who reported a detailed analysis of clonal evolution in adult BCP-ALL with different contributions of de novo V(D)J recombination and V<sub>H</sub> replacement in different BCP-ALL subtypes. V<sub>H</sub> replacement can occur repeatedly leading to prolonged CDR3 regions due to footprint nucleotides left behind at each V<sub>H</sub> replacement step located between the canonical and the cryptic recombination signal sequence.<span><sup>20</sup></span> The present study extends the observation of proximally biased clonal evolution to cases of infant and pediatric BCP-ALL carrying KMT2A-r.</p><p>DJ<sub>H</sub> recombination is the first step in V(D)J recombination<span><sup>13</sup></span> and the realization of a fully randomized immunoglobulin repertoire is dependent on IGH locus decontraction controlled by <i>PAX5</i> and <i>WAPL</i>.<span><sup>11, 12</sup></span> Therefore, both the more frequent occurrence of de novo DJ<sub>H</sub> recombination as well as the proximal bias in V(D)J recombination suggest a more primitive stage of differentiation of KMT2A-r BCP-ALL. These findings have implications for the clinical management of KMT2A-r BCP-ALL cases as clonal evolution interferes with reliable detection of MRD based on IG rearrangements. An obvious alternative would be the detection of fusion products and co-mutations.</p><p>Heiko Müller performed the analyses and wrote the manuscript. Wencke Walter, Stephan Hutter, Niroshan Nadarajah, and Manja Meggendorfer generated the NGS data. Constance Bär and Frank Dicker contributed expertise in BCR rearrangement analyses. Qingsong Gao, Ilaria Iacobucci, and Charles G. Mullighan provided the WTS data for the validation cohort. Wolfgang Kern, Torsten Haferlach, and Claudia Haferlach supervised and coordinated the research. All authors read and approved the final version of the manuscript.</p><p>Torsten Haferlach, Claudia Haferlach, and Wolfgang Kern declare part ownership of Munich Leukemia Laboratory (MLL). Heiko Müller, Frank Dicker, Constance Bär, Wencke Walter, Stephan Hutter, Niroshan Nadarajah, and Manja Meggendorfer are employed by the MLL. Charles G. Mullighan received research funding from Loxo Oncology, Pfizer, AbbVie; honoraria from Amgen and Illumina, and holds stock in Amgen.</p><p>This study was supported by the American Lebanese and Syrian Associated Charities of St. Jude Children's Research Hospital and NCI Grant R35 CA197695 (to C. G. M.).</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":null,"pages":null},"PeriodicalIF":7.6000,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hem3.71","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"HemaSphere","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hem3.71","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
We report the analysis of 379 cases of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) using whole-transcriptome sequencing data (Table S1 and Supporting Information S1: Methods). In 48 adult, 36 pediatric, and 37 infant cases of BCP-ALL carrying t(4;11)(q21;q23)/KMT2A::AFF1 rearrangements (KMT2A-r), we observed strongly favored usage of proximal IGHV genes in V(D)J recombination and more abundant de novo DJH recombination than in other BCP-ALL subtypes. This finding has implications for the detection of measurable residual disease (MRD) in clinical practice as MRD-guided treatment choices have proved to provide valuable guidance in a disease that is still associated with poor prognosis in all age categories.
BCP-ALL carrying KMT2A-r is an aggressive leukemia with poor prognosis characterized by the sudden occurrence of very high white blood cell counts, a slight preference for female patients, rapid progression, and significantly shorter survival than KMT2A-r-negative patients.1, 2 Treatment options that significantly prolong the survival of affected patients are limited to allogeneic stem cell transplantation.2 The incidence of KMT2A-r BCP-ALL is estimated between 4% and 10% in adults and 3% and 4% in childhood.3
KMT2A is a histone methyl transferase of the trithorax group involved in the establishment of epigenetic memory. It catalyzes H3K4 methylation of a large number of physiological targets including HOX genes, supporting activation of their expression.4, 5 In leukemogenic fusions, the N-terminal portion of KMT2A is fused in frame to more than 100 fusion partners.6 In the fusion product, the catalytic SET domain of KMT2A is lost. The most frequently observed fusion partners favor the interaction of the fusion product with another histone methyl transferase (DOT1L) that catalyzes H3K79 methylation. As a consequence, proper regulation of target genes activated in this aberrant fashion appears to be disturbed in cells carrying KMT2A-r.4, 5, 7, 8
Proximally biased V(D)J recombination was first described in pre-B-cell lines9 and later shown to depend on Pax5 function.10 It is now understood that the generation of a randomized immunoglobulin repertoire depends on chromatin modifications at the IGH locus controlled by PAX5 and its target, WAPL.11, 12 In addition to classical V(D)J recombination,13 B-cell receptors (BCRs) are known to be modified by direct VH to VHDJH recombination (VH replacement)14, 15 and this process is known to occur also in BCP-ALL cells.16-18 Whether the relative contribution of V(D)J recombination and VH replacement to clonal evolution of BCRs displays BCP-ALL subtype specificity is currently a matter of investigation.19, 20
During the analysis of BCR rearrangements in RNA-sequencing (RNA-Seq) data from BCP-ALL samples, we noticed an unusual abundance of rearrangements involving IGHV6-1 in samples carrying KMT2A-r fusion genes. To quantify this observation, we employed MiXCR analysis of RNA-Seq reads (Figure 1). The number of RNA-Seq reads mapping to a particular IGHV gene by MiXCR was used to quantify the expression levels of individual IGHV genes in a sample. The heatmap in Figure 1 shows the results of this analysis. In this heatmap, the IGHV genes are ordered according to their proximity in terms of genomic distance to the cluster of DJH segments in the IGH locus. While for most samples, the expression level of IGHV genes appears to be independent of their genomic position, in KMT2A-r samples the most proximal IGHV gene IGHV6-1 displays significantly higher expression levels as compared to distal ones. This observation is true for KMT2A-r samples of all age classes.
We employed junction analysis of MiXCR-derived nucleotide sequences of rearranged IGH alleles to test whether there are BCP-ALL-subtype-specific differences in V(D)J recombination. IMGT-V-QUEST was used for this purpose, which identifies as junctions the nucleotides coding for the amino acids encompassing the anchor positions of the CDR3 region (C104-W118) and maps the nucleotides to the VH-N-D-N-JH components of the CDR3 region (Table S2). The results are shown in Figure 2. We observed that KMT2A-r samples of all age classes have a median number of three DNJH stems per sample (Figure 2A). The only subtype with a similar median number of DNJH stems per sample is t(1;19)/TCF3::PBX1. At the other end of the spectrum is the DUX4 subtype where multiple DNJH stems per sample were not detected. Furthermore, the CDR3 regions at the nucleotide level identified in KMT2A-r samples are shorter than in most other BCP-ALL subtypes (Figure 2B).
We conclude that V(D)J recombination is proximally biased in samples with KMT2A-r of all age classes. Proximally biased V(D)J recombination leads to preferential usage of IGHV6-1 in BCR rearrangements. Indeed, up to 50% of samples with KMT2A-r harbor BCRs involving IGHV6-1.
We detected subtype specificity in the clonal evolution of BCP-ALL. We observed more DNJH stems in KMT2A-r samples as compared to other types of BCP-ALL, and the CDR3 regions in KMT2A-r samples are shorter. This is in line with the observations reported by Darzentas et al.,19, 20 who reported a detailed analysis of clonal evolution in adult BCP-ALL with different contributions of de novo V(D)J recombination and VH replacement in different BCP-ALL subtypes. VH replacement can occur repeatedly leading to prolonged CDR3 regions due to footprint nucleotides left behind at each VH replacement step located between the canonical and the cryptic recombination signal sequence.20 The present study extends the observation of proximally biased clonal evolution to cases of infant and pediatric BCP-ALL carrying KMT2A-r.
DJH recombination is the first step in V(D)J recombination13 and the realization of a fully randomized immunoglobulin repertoire is dependent on IGH locus decontraction controlled by PAX5 and WAPL.11, 12 Therefore, both the more frequent occurrence of de novo DJH recombination as well as the proximal bias in V(D)J recombination suggest a more primitive stage of differentiation of KMT2A-r BCP-ALL. These findings have implications for the clinical management of KMT2A-r BCP-ALL cases as clonal evolution interferes with reliable detection of MRD based on IG rearrangements. An obvious alternative would be the detection of fusion products and co-mutations.
Heiko Müller performed the analyses and wrote the manuscript. Wencke Walter, Stephan Hutter, Niroshan Nadarajah, and Manja Meggendorfer generated the NGS data. Constance Bär and Frank Dicker contributed expertise in BCR rearrangement analyses. Qingsong Gao, Ilaria Iacobucci, and Charles G. Mullighan provided the WTS data for the validation cohort. Wolfgang Kern, Torsten Haferlach, and Claudia Haferlach supervised and coordinated the research. All authors read and approved the final version of the manuscript.
Torsten Haferlach, Claudia Haferlach, and Wolfgang Kern declare part ownership of Munich Leukemia Laboratory (MLL). Heiko Müller, Frank Dicker, Constance Bär, Wencke Walter, Stephan Hutter, Niroshan Nadarajah, and Manja Meggendorfer are employed by the MLL. Charles G. Mullighan received research funding from Loxo Oncology, Pfizer, AbbVie; honoraria from Amgen and Illumina, and holds stock in Amgen.
This study was supported by the American Lebanese and Syrian Associated Charities of St. Jude Children's Research Hospital and NCI Grant R35 CA197695 (to C. G. M.).
期刊介绍:
HemaSphere, as a publication, is dedicated to disseminating the outcomes of profoundly pertinent basic, translational, and clinical research endeavors within the field of hematology. The journal actively seeks robust studies that unveil novel discoveries with significant ramifications for hematology.
In addition to original research, HemaSphere features review articles and guideline articles that furnish lucid synopses and discussions of emerging developments, along with recommendations for patient care.
Positioned as the foremost resource in hematology, HemaSphere augments its offerings with specialized sections like HemaTopics and HemaPolicy. These segments engender insightful dialogues covering a spectrum of hematology-related topics, including digestible summaries of pivotal articles, updates on new therapies, deliberations on European policy matters, and other noteworthy news items within the field. Steering the course of HemaSphere are Editor in Chief Jan Cools and Deputy Editor in Chief Claire Harrison, alongside the guidance of an esteemed Editorial Board comprising international luminaries in both research and clinical realms, each representing diverse areas of hematologic expertise.